Business Context and Reporting Period
This Form 8-K was filed by Aclaris Therapeutics, Inc. on March 23, 2023. The report discloses an amendment to a consulting services agreement with Frank Ruffo, the company's former Chief Financial Officer.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, or debt metrics. The only specific financial data disclosed relates to the amended consulting agreement:
- Consulting Fee: $12,500 per month.
- Equity Vesting: The last day of vesting for outstanding equity awards was March 2, 2023; no further awards will vest.
Material Changes
The primary material change is the extension of the consulting term with Frank Ruffo from March 3, 2023, through June 30, 2023. This amendment formalizes the compensation and equity vesting cessation for the former CFO.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on business outlook, or discussion of general risks and contingencies. The document is strictly limited to the terms of the executive compensation amendment.
Investor Verification Checklist
- Verify the total cash outflow for the extended consulting period (April through June 2023).
- Confirm the status of any remaining unvested equity awards for Frank Ruffo as of March 2, 2023.
- Review the full text of Exhibit 10.1 for any additional terms not summarized in the 8-K.
- Check subsequent filings for the appointment of a new Chief Financial Officer.